Cargando…
Experience with abatacept in refractory lupus nephritis
Lupus nephritis is a major cause of morbidity in patients with systemic lupus erythematosus. Responsiveness to treatment is crucial to avoid chronic kidney disease. New molecules have been developed in recent years to improve renal survival rates. Biological therapies as coadjutant to conventional i...
Autores principales: | Calatayud, Emma, Montomoli, Marco, Ávila, Ana, Sancho Calabuig, Asunción, Alegre-Sancho, Juan José |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Springer Berlin Heidelberg
2023
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10587212/ https://www.ncbi.nlm.nih.gov/pubmed/37650922 http://dx.doi.org/10.1007/s00296-023-05389-0 |
Ejemplares similares
-
Adalimumab-Induced Lupus Nephritis: Case Report and Review of the Literature
por: Kazzi, Brigitte, et al.
Publicado: (2022) -
Management of refractory lupus nephritis: challenges and solutions
por: Yo, JH, et al.
Publicado: (2019) -
Secukinumab on Refractory Lupus Nephritis
por: Costa, Rita, et al.
Publicado: (2021) -
Daratumumab monotherapy for refractory lupus nephritis
por: Roccatello, Dario, et al.
Publicado: (2023) -
Subacute cutaneous lupus erythematosus and systemic lupus erythematosus associated with abatacept
por: Tarazi, Meera, et al.
Publicado: (2018)